Adults with refractory chronic cough who received twice-daily camlipixant had decreases in cough frequency and better scores ...

Trevi Therapeutics (TRVI) stock has rocketed up over 63% in the past week on news that recent clinical trials have shown promising results. The ...

Trevi Therapeutics posted a wider loss in the fourth quarter as it increased spending on trials for chronic cough treatments. The biopharmaceutical company posted a loss of $11.4 million, or 11 cents ...

A chronic dry cough is a common symptom of ... Read more about the best natural cough remedies. Healthline has strict sourcing guidelines and relies on peer-reviewed studies, academic research ...

Trevi Therapeutics, Inc. (NASDAQ:TRVI) reported topline results from its Phase 2a RIVER trial of Haduvio (oral nalbuphine ER) for the treatment of patients with refractory chronic cough (N=66).

Causes of a chronic cough, which persists for more than eight weeks, include air pollution, asthma or allergies, chronic obstructive pulmonary disease (COPD), and gastroesophageal reflux disease ...

But a chronic cough often disrupts speeches or training ... It may take time to find the best treatment as patients and doctors step through the options. And Catherine says don't be discouraged ...

(NASDAQ:TRVI) reported topline results from its Phase 2a RIVER trial of Haduvio (oral nalbuphine ER) for the treatment of patients with refractory chronic cough (N=66). Haduvio met the primary ...